Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments
Identifieur interne : 000423 ( Pmc/Corpus ); précédent : 000422; suivant : 000424Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments
Auteurs : Lianrong Xu ; Yan Zhao ; Fei Pan ; Mengxia Zhu ; Liqin Yao ; Yan Liu ; Jiangfang Feng ; Jie Xiong ; Xiuhua Chen ; Fanggang Ren ; Yanhong Tan ; Hongwei WangSource :
- BioMed Research International [ 2314-6133 ] ; 2019.
Abstract
Nuclear factor erythroid 2-related factor 2 (Nrf2) is involved in tumor drug resistance, but its role in imatinib resistance of chronic myeloid leukemia (CML) remains elusive. We aimed to investigate the effects of Nrf2 on drug sensitivity, thioredoxin reductase (TrxR) expression, reactive oxygen species (ROS) production, and apoptosis induction in imatinib-resistant CML K562/G01 cells and explored their potential mechanisms. Stable K562/G01 cells with knockdown of Nrf2 were established by infection of siRNA-expressing lentivirus. The mRNA and protein expression levels of Nrf2 and TrxR were determined by real-time quantitative polymerase chain reaction and western blot, respectively. ROS generation and apoptosis were assayed by flow cytometry, while drug sensitivity was measured by the Cell Counting Kit-8 assay. Imatinib-resistant K562/G01 cells had higher levels of Nrf2 expression than the parental K562 cells at both mRNA and protein levels. Expression levels of Nrf2 and TrxR were positively correlated in K562/G01 cells. Knockdown of Nrf2 in K562/G01 cells enhanced the intracellular ROS level, suppressed cell proliferation, and increased apoptosis in response to imatinib treatments. Nrf2 expression contributes to the imatinib resistance of K562/G01 cells and is positively correlated with TrxR expression. Targeted inhibition of the Nrf2-TrxR axis represents a potential therapeutic approach for imatinib-resistant CML.
Url:
DOI: 10.1155/2019/6502793
PubMed: 31828114
PubMed Central: 6885806
Links to Exploration step
PMC:6885806Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments</title><author><name sortKey="Xu, Lianrong" sort="Xu, Lianrong" uniqKey="Xu L" first="Lianrong" last="Xu">Lianrong Xu</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Zhao, Yan" sort="Zhao, Yan" uniqKey="Zhao Y" first="Yan" last="Zhao">Yan Zhao</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Pan, Fei" sort="Pan, Fei" uniqKey="Pan F" first="Fei" last="Pan">Fei Pan</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Zhu, Mengxia" sort="Zhu, Mengxia" uniqKey="Zhu M" first="Mengxia" last="Zhu">Mengxia Zhu</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Yao, Liqin" sort="Yao, Liqin" uniqKey="Yao L" first="Liqin" last="Yao">Liqin Yao</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Liu, Yan" sort="Liu, Yan" uniqKey="Liu Y" first="Yan" last="Liu">Yan Liu</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Feng, Jiangfang" sort="Feng, Jiangfang" uniqKey="Feng J" first="Jiangfang" last="Feng">Jiangfang Feng</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Xiong, Jie" sort="Xiong, Jie" uniqKey="Xiong J" first="Jie" last="Xiong">Jie Xiong</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Chen, Xiuhua" sort="Chen, Xiuhua" uniqKey="Chen X" first="Xiuhua" last="Chen">Xiuhua Chen</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Ren, Fanggang" sort="Ren, Fanggang" uniqKey="Ren F" first="Fanggang" last="Ren">Fanggang Ren</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Tan, Yanhong" sort="Tan, Yanhong" uniqKey="Tan Y" first="Yanhong" last="Tan">Yanhong Tan</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Wang, Hongwei" sort="Wang, Hongwei" uniqKey="Wang H" first="Hongwei" last="Wang">Hongwei Wang</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31828114</idno><idno type="pmc">6885806</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885806</idno><idno type="RBID">PMC:6885806</idno><idno type="doi">10.1155/2019/6502793</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000423</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000423</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments</title><author><name sortKey="Xu, Lianrong" sort="Xu, Lianrong" uniqKey="Xu L" first="Lianrong" last="Xu">Lianrong Xu</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Zhao, Yan" sort="Zhao, Yan" uniqKey="Zhao Y" first="Yan" last="Zhao">Yan Zhao</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Pan, Fei" sort="Pan, Fei" uniqKey="Pan F" first="Fei" last="Pan">Fei Pan</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Zhu, Mengxia" sort="Zhu, Mengxia" uniqKey="Zhu M" first="Mengxia" last="Zhu">Mengxia Zhu</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Yao, Liqin" sort="Yao, Liqin" uniqKey="Yao L" first="Liqin" last="Yao">Liqin Yao</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Liu, Yan" sort="Liu, Yan" uniqKey="Liu Y" first="Yan" last="Liu">Yan Liu</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Feng, Jiangfang" sort="Feng, Jiangfang" uniqKey="Feng J" first="Jiangfang" last="Feng">Jiangfang Feng</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Xiong, Jie" sort="Xiong, Jie" uniqKey="Xiong J" first="Jie" last="Xiong">Jie Xiong</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Chen, Xiuhua" sort="Chen, Xiuhua" uniqKey="Chen X" first="Xiuhua" last="Chen">Xiuhua Chen</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Ren, Fanggang" sort="Ren, Fanggang" uniqKey="Ren F" first="Fanggang" last="Ren">Fanggang Ren</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Tan, Yanhong" sort="Tan, Yanhong" uniqKey="Tan Y" first="Yanhong" last="Tan">Yanhong Tan</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author><author><name sortKey="Wang, Hongwei" sort="Wang, Hongwei" uniqKey="Wang H" first="Hongwei" last="Wang">Hongwei Wang</name><affiliation><nlm:aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</nlm:aff></affiliation></author></analytic><series><title level="j">BioMed Research International</title><idno type="ISSN">2314-6133</idno><idno type="eISSN">2314-6141</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Nuclear factor erythroid 2-related factor 2 (Nrf2) is involved in tumor drug resistance, but its role in imatinib resistance of chronic myeloid leukemia (CML) remains elusive. We aimed to investigate the effects of Nrf2 on drug sensitivity, thioredoxin reductase (TrxR) expression, reactive oxygen species (ROS) production, and apoptosis induction in imatinib-resistant CML K562/G01 cells and explored their potential mechanisms. Stable K562/G01 cells with knockdown of Nrf2 were established by infection of siRNA-expressing lentivirus. The mRNA and protein expression levels of Nrf2 and TrxR were determined by real-time quantitative polymerase chain reaction and western blot, respectively. ROS generation and apoptosis were assayed by flow cytometry, while drug sensitivity was measured by the Cell Counting Kit-8 assay. Imatinib-resistant K562/G01 cells had higher levels of Nrf2 expression than the parental K562 cells at both mRNA and protein levels. Expression levels of Nrf2 and TrxR were positively correlated in K562/G01 cells. Knockdown of Nrf2 in K562/G01 cells enhanced the intracellular ROS level, suppressed cell proliferation, and increased apoptosis in response to imatinib treatments. Nrf2 expression contributes to the imatinib resistance of K562/G01 cells and is positively correlated with TrxR expression. Targeted inhibition of the Nrf2-TrxR axis represents a potential therapeutic approach for imatinib-resistant CML.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Flis, S" uniqKey="Flis S">S. Flis</name></author><author><name sortKey="Chojnacki, T" uniqKey="Chojnacki T">T. Chojnacki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stagno, F" uniqKey="Stagno F">F. Stagno</name></author><author><name sortKey="Stella, S" uniqKey="Stella S">S. Stella</name></author><author><name sortKey="Spitaleri, A" uniqKey="Spitaleri A">A. Spitaleri</name></author><author><name sortKey="Pennisi, M S" uniqKey="Pennisi M">M. S. Pennisi</name></author><author><name sortKey="Di Raimondo, F" uniqKey="Di Raimondo F">F. Di Raimondo</name></author><author><name sortKey="Vigneri, P" uniqKey="Vigneri P">P. Vigneri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Milojkovic, D" uniqKey="Milojkovic D">D. Milojkovic</name></author><author><name sortKey="Apperley, J" uniqKey="Apperley J">J. Apperley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, T" uniqKey="Kim T">T. Kim</name></author><author><name sortKey="Tyndel, M S" uniqKey="Tyndel M">M. S. Tyndel</name></author><author><name sortKey="Kim, H J" uniqKey="Kim H">H. J. Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soverini, S" uniqKey="Soverini S">S. Soverini</name></author><author><name sortKey="Mancini, M" uniqKey="Mancini M">M. Mancini</name></author><author><name sortKey="Bavaro, L" uniqKey="Bavaro L">L. Bavaro</name></author><author><name sortKey="Cavo, M" uniqKey="Cavo M">M. Cavo</name></author><author><name sortKey="Martinelli, G" uniqKey="Martinelli G">G. Martinelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Itoh, K" uniqKey="Itoh K">K. Itoh</name></author><author><name sortKey="Wakabayashi, N" uniqKey="Wakabayashi N">N. Wakabayashi</name></author><author><name sortKey="Katoh, Y" uniqKey="Katoh Y">Y. Katoh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Neumann, C A" uniqKey="Neumann C">C. A. Neumann</name></author><author><name sortKey="Cao, J" uniqKey="Cao J">J. Cao</name></author><author><name sortKey="Manevich, Y" uniqKey="Manevich Y">Y. Manevich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abdul Aziz, A" uniqKey="Abdul Aziz A">A. Abdul-Aziz</name></author><author><name sortKey="Macewan, D J" uniqKey="Macewan D">D. J. MacEwan</name></author><author><name sortKey="Bowles, K M" uniqKey="Bowles K">K. M. Bowles</name></author><author><name sortKey="Rushworth, S A" uniqKey="Rushworth S">S. A. Rushworth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Radwan, S M" uniqKey="Radwan S">S. M. Radwan</name></author><author><name sortKey="Hamdy, N M" uniqKey="Hamdy N">N. M. Hamdy</name></author><author><name sortKey="Hegab, H M" uniqKey="Hegab H">H. M. Hegab</name></author><author><name sortKey="El Mesallamy, H O" uniqKey="El Mesallamy H">H. O. El-Mesallamy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhumina, A" uniqKey="Zhumina A">A. Zhumina</name></author><author><name sortKey="Pogossyan, G" uniqKey="Pogossyan G">G. Pogossyan</name></author><author><name sortKey="Li, K" uniqKey="Li K">K. Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, P" uniqKey="Lin P">P. Lin</name></author><author><name sortKey="Ren, Y" uniqKey="Ren Y">Y. Ren</name></author><author><name sortKey="Yan, X" uniqKey="Yan X">X. Yan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Su, X" uniqKey="Su X">X. Su</name></author><author><name sortKey="Jiang, X" uniqKey="Jiang X">X. Jiang</name></author><author><name sortKey="Meng, L" uniqKey="Meng L">L. Meng</name></author><author><name sortKey="Dong, X" uniqKey="Dong X">X. Dong</name></author><author><name sortKey="Shen, Y" uniqKey="Shen Y">Y. Shen</name></author><author><name sortKey="Xin, Y" uniqKey="Xin Y">Y. Xin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bai, X" uniqKey="Bai X">X. Bai</name></author><author><name sortKey="Chen, Y" uniqKey="Chen Y">Y. Chen</name></author><author><name sortKey="Hou, X" uniqKey="Hou X">X. Hou</name></author><author><name sortKey="Huang, M" uniqKey="Huang M">M. Huang</name></author><author><name sortKey="Jin, J" uniqKey="Jin J">J. Jin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rushworth, S A" uniqKey="Rushworth S">S. A. Rushworth</name></author><author><name sortKey="Macewan, D J" uniqKey="Macewan D">D. J. Macewan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rushworth, S A" uniqKey="Rushworth S">S. A. Rushworth</name></author><author><name sortKey="Zaitseva, L" uniqKey="Zaitseva L">L. Zaitseva</name></author><author><name sortKey="Murray, M Y" uniqKey="Murray M">M. Y. Murray</name></author><author><name sortKey="Shah, N M" uniqKey="Shah N">N. M. Shah</name></author><author><name sortKey="Bowles, K M" uniqKey="Bowles K">K. M. Bowles</name></author><author><name sortKey="Macewan, D J" uniqKey="Macewan D">D. J. MacEwan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karathedath, S" uniqKey="Karathedath S">S. Karathedath</name></author><author><name sortKey="Rajamani, B M" uniqKey="Rajamani B">B. M. Rajamani</name></author><author><name sortKey="Aalam, S M M" uniqKey="Aalam S">S. M. M. Aalam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xu, X" uniqKey="Xu X">X. Xu</name></author><author><name sortKey="Zhang, X" uniqKey="Zhang X">X. Zhang</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y. Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, J" uniqKey="Zhang J">J. Zhang</name></author><author><name sortKey="Li, X" uniqKey="Li X">X. Li</name></author><author><name sortKey="Han, X" uniqKey="Han X">X. Han</name></author><author><name sortKey="Liu, R" uniqKey="Liu R">R. Liu</name></author><author><name sortKey="Fang, J" uniqKey="Fang J">J. Fang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kamal, A M" uniqKey="Kamal A">A. M. Kamal</name></author><author><name sortKey="El Hefny, N H" uniqKey="El Hefny N">N. H. El-Hefny</name></author><author><name sortKey="Hegab, H M" uniqKey="Hegab H">H. M. Hegab</name></author><author><name sortKey="El Mesallamy, H O" uniqKey="El Mesallamy H">H. O. El-Mesallamy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, J J" uniqKey="Liu J">J. J. Liu</name></author><author><name sortKey="Liu, Q" uniqKey="Liu Q">Q. Liu</name></author><author><name sortKey="Wei, H L" uniqKey="Wei H">H. L. Wei</name></author><author><name sortKey="Yi, J" uniqKey="Yi J">J. Yi</name></author><author><name sortKey="Zhao, H S" uniqKey="Zhao H">H. S. Zhao</name></author><author><name sortKey="Gao, L P" uniqKey="Gao L">L. P. Gao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pan, F" uniqKey="Pan F">F. Pan</name></author><author><name sortKey="Xu, L R" uniqKey="Xu L">L. R. Xu</name></author><author><name sortKey="Wang, H W" uniqKey="Wang H">H. W. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pan, F" uniqKey="Pan F">F. Pan</name></author><author><name sortKey="Xu, L R" uniqKey="Xu L">L. R. Xu</name></author><author><name sortKey="Wang, H W" uniqKey="Wang H">H. W. Wang</name></author><author><name sortKey="Zhu, M X" uniqKey="Zhu M">M. X. Zhu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Qi, J" uniqKey="Qi J">J. Qi</name></author><author><name sortKey="Peng, H" uniqKey="Peng H">H. Peng</name></author><author><name sortKey="Gu, Z L" uniqKey="Gu Z">Z. L. Gu</name></author><author><name sortKey="Liang, Z Q" uniqKey="Liang Z">Z. Q. Liang</name></author><author><name sortKey="Yang, C Z" uniqKey="Yang C">C. Z. Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Livak, K J" uniqKey="Livak K">K. J. Livak</name></author><author><name sortKey="Schmittgen, T D" uniqKey="Schmittgen T">T. D. Schmittgen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bonovolias, I D" uniqKey="Bonovolias I">I. D. Bonovolias</name></author><author><name sortKey="Tsiftsoglou, A S" uniqKey="Tsiftsoglou A">A. S. Tsiftsoglou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nagai, T" uniqKey="Nagai T">T. Nagai</name></author><author><name sortKey="Kikuchi, S" uniqKey="Kikuchi S">S. Kikuchi</name></author><author><name sortKey="Ohmine, K" uniqKey="Ohmine K">K. Ohmine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cebula, M" uniqKey="Cebula M">M. Cebula</name></author><author><name sortKey="Schmidt, E E" uniqKey="Schmidt E">E. E. Schmidt</name></author><author><name sortKey="Arner, E S J" uniqKey="Arner E">E. S. J. Arnér</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raninga, P V" uniqKey="Raninga P">P. V. Raninga</name></author><author><name sortKey="Di Trapani, G" uniqKey="Di Trapani G">G. Di Trapani</name></author><author><name sortKey="Vuckovic, S" uniqKey="Vuckovic S">S. Vuckovic</name></author><author><name sortKey="Tonissen, K F" uniqKey="Tonissen K">K. F. Tonissen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y. Liu</name></author><author><name sortKey="Xu, L R" uniqKey="Xu L">L. R. Xu</name></author><author><name sortKey="Zhu, M X" uniqKey="Zhu M">M. X. Zhu</name></author><author><name sortKey="Pan, F" uniqKey="Pan F">F. Pan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Renschler, M F" uniqKey="Renschler M">M. F. Renschler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Toler, S M" uniqKey="Toler S">S. M. Toler</name></author><author><name sortKey="Noe, D" uniqKey="Noe D">D. Noe</name></author><author><name sortKey="Sharma, A" uniqKey="Sharma A">A. Sharma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sattler, M" uniqKey="Sattler M">M. Sattler</name></author><author><name sortKey="Verma, S" uniqKey="Verma S">S. Verma</name></author><author><name sortKey="Shrikhande, G" uniqKey="Shrikhande G">G. Shrikhande</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, J H" uniqKey="Kim J">J. H. Kim</name></author><author><name sortKey="Chu, S C" uniqKey="Chu S">S. C. Chu</name></author><author><name sortKey="Gramlich, J L" uniqKey="Gramlich J">J. L. Gramlich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="No, J H" uniqKey="No J">J. H. No</name></author><author><name sortKey="Kim, Y B" uniqKey="Kim Y">Y. B. Kim</name></author><author><name sortKey="Song, Y S" uniqKey="Song Y">Y. S. Song</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raninga, P V" uniqKey="Raninga P">P. V. Raninga</name></author><author><name sortKey="Di Trapani, G" uniqKey="Di Trapani G">G. Di Trapani</name></author><author><name sortKey="Vuckovic, S" uniqKey="Vuckovic S">S. Vuckovic</name></author><author><name sortKey="Bhatia, M" uniqKey="Bhatia M">M. Bhatia</name></author><author><name sortKey="Tonissen, K F" uniqKey="Tonissen K">K. F. Tonissen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cho, J M" uniqKey="Cho J">J. M. Cho</name></author><author><name sortKey="Manandhar, S" uniqKey="Manandhar S">S. Manandhar</name></author><author><name sortKey="Lee, H R" uniqKey="Lee H">H. R. Lee</name></author><author><name sortKey="Park, H M" uniqKey="Park H">H. M. Park</name></author><author><name sortKey="Kwak, M K" uniqKey="Kwak M">M. K. Kwak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, K" uniqKey="Zhang K">K. Zhang</name></author><author><name sortKey="Yang, H" uniqKey="Yang H">H. Yang</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y. Wang</name></author><author><name sortKey="Ma, L" uniqKey="Ma L">L. Ma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shibata, T" uniqKey="Shibata T">T. Shibata</name></author><author><name sortKey="Kokubu, A" uniqKey="Kokubu A">A. Kokubu</name></author><author><name sortKey="Gotoh, M" uniqKey="Gotoh M">M. Gotoh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Akhdar, H" uniqKey="Akhdar H">H. Akhdar</name></author><author><name sortKey="Loyer, P" uniqKey="Loyer P">P. Loyer</name></author><author><name sortKey="Rauch, C" uniqKey="Rauch C">C. Rauch</name></author><author><name sortKey="Corlu, A" uniqKey="Corlu A">A. Corlu</name></author><author><name sortKey="Guillouzo, A" uniqKey="Guillouzo A">A. Guillouzo</name></author><author><name sortKey="Morel, F" uniqKey="Morel F">F. Morel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, X J" uniqKey="Wang X">X. J. Wang</name></author><author><name sortKey="Sun, Z" uniqKey="Sun Z">Z. Sun</name></author><author><name sortKey="Villeneuve, N F" uniqKey="Villeneuve N">N. F. Villeneuve</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31828114</article-id><article-id pub-id-type="pmc">6885806</article-id><article-id pub-id-type="doi">10.1155/2019/6502793</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5279-6421</contrib-id><name><surname>Xu</surname><given-names>Lianrong</given-names></name><email>xulrdoctor@sxmu.edu.cn</email><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Fei</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Mengxia</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Liqin</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Jiangfang</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><name><surname>Xiong</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiuhua</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Fanggang</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Yanhong</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2902-591X</contrib-id><name><surname>Wang</surname><given-names>Hongwei</given-names></name><xref ref-type="aff" rid="I1"></xref></contrib></contrib-group><aff id="I1">Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Nadia M. Hamdy</p></fn></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>18</day><month>11</month><year>2019</year></pub-date><volume>2019</volume><elocation-id>6502793</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>30</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>Copyright © 2019 Lianrong Xu et al.</copyright-statement><copyright-year>2019</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Nuclear factor erythroid 2-related factor 2 (Nrf2) is involved in tumor drug resistance, but its role in imatinib resistance of chronic myeloid leukemia (CML) remains elusive. We aimed to investigate the effects of Nrf2 on drug sensitivity, thioredoxin reductase (TrxR) expression, reactive oxygen species (ROS) production, and apoptosis induction in imatinib-resistant CML K562/G01 cells and explored their potential mechanisms. Stable K562/G01 cells with knockdown of Nrf2 were established by infection of siRNA-expressing lentivirus. The mRNA and protein expression levels of Nrf2 and TrxR were determined by real-time quantitative polymerase chain reaction and western blot, respectively. ROS generation and apoptosis were assayed by flow cytometry, while drug sensitivity was measured by the Cell Counting Kit-8 assay. Imatinib-resistant K562/G01 cells had higher levels of Nrf2 expression than the parental K562 cells at both mRNA and protein levels. Expression levels of Nrf2 and TrxR were positively correlated in K562/G01 cells. Knockdown of Nrf2 in K562/G01 cells enhanced the intracellular ROS level, suppressed cell proliferation, and increased apoptosis in response to imatinib treatments. Nrf2 expression contributes to the imatinib resistance of K562/G01 cells and is positively correlated with TrxR expression. Targeted inhibition of the Nrf2-TrxR axis represents a potential therapeutic approach for imatinib-resistant CML.</p></abstract><funding-group><award-group><funding-source>Natural Science Foundation of Shanxi Province</funding-source><award-id>2012011038-5</award-id></award-group><award-group><funding-source>Shanxi Medical and Health Science and Technology Plan Project</funding-source><award-id>20100202</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome (Ph) resulting from reciprocal translocation between chromosome 9 and chromosome 22 [t(9; 22) (q34; q11)], eventually forming the breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) oncogene, which encodes a constitutively activated tyrosine kinase [<xref rid="B1" ref-type="bibr">1</xref>]. Imatinib mesylate (IM), as the first-generation tyrosine kinase inhibitors (TKIs), targeted represses the tyrosine kinase activity of BCR/ABL fusion protein [<xref rid="B2" ref-type="bibr">2</xref>]. Either administered alone or combined with other therapies, it has become one of the first-line drugs for the targeted treatment of CML [<xref rid="B3" ref-type="bibr">3</xref>]. However, there are still 15% to 25% of patients having primary or secondary drug resistance due to T315I mutation, clonal evolution, overexpression or hyperactivation of some members of the SRC family of kinases, activation of additional pro-oncogenic pathways, leukemia stem cell intrinsic resistance, and mutations in epigenetic regulators [<xref rid="B3" ref-type="bibr">3</xref>–<xref rid="B5" ref-type="bibr">5</xref>]. Therefore, it is urgent to explore the solutions for overcoming the imatinib resistance in CML treatments.</p><p>Nuclear factor erythroid 2-related factor 2 (Nrf2) can activate the expression of a battery of antioxidant response element-dependent genes, such as thioredoxin reductase (TrxR), to regulate cellular defense against electrophilic and oxidative stress [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Overexpressed or hyperactivated Nrf2 can participate in tumorigenesis by helping cells escape from stress or by directly promoting cell survival, proliferation, and even metastasis [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>]. Notably, Nrf2 was persistently overexpressed in CML and acute myeloid leukemia (AML) patients [<xref rid="B10" ref-type="bibr">10</xref>]. Nrf2 expression was higher in high-risk myelodysplastic syndromes (MDS) patients than that of low-risk patients [<xref rid="B11" ref-type="bibr">11</xref>]. In addition, high Nrf2 levels were correlated with poor outcomes in MDS patients [<xref rid="B11" ref-type="bibr">11</xref>].</p><p>Moreover, Nrf2 plays a vital role in the chemoresistance of tumors to several drugs by some ways, such as protecting cells from the production of ROS or electrophiles, preventing the intracellular accumulation of drugs, and actively inhibiting apoptosis and regulating drug-metabolizing enzymes and efflux transporters [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. Nrf2 can overcome apoptosis and reduce the susceptibility of AML towards chemotherapeutic agents [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. High Nrf2 expression is related with chemoresistance to Ara-C, DNR, and ATO in AML cell lines and primary AML cells, and knockdown of Nrf2 can increase AML cells predisposition to chemotherapy drugs [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B16" ref-type="bibr">16</xref>]. Some studies also explored to reverse the drug resistance of human myelogenous leukemia cells and MDS by using Nrf2 inhibitors [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B17" ref-type="bibr">17</xref>].</p><p>Thioredoxin reductase (TrxR) catalyzes to generate reduced oxidized thioredoxins (Trxs) to regulate diverse cellular redox events during cell proliferation, differentiation, and death [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. TrxR is often overexpressed in many human cancers and seems to affect the aggressiveness of the tumors [<xref rid="B18" ref-type="bibr">18</xref>]. It has been found that the expression of TrxR in doxorubicin-resistant K562 cells is higher than that in the parental sensitive cells and the TrxR inhibitor can reverse doxorubicin resistance [<xref rid="B20" ref-type="bibr">20</xref>]. In our previous studies, we found that the Nrf2 mRNA expression was upregulated in the human CML cell line K562 and the bone marrow cells of CML patients, and it was gradually elevated along with the progression of the disease stages. In addition, TrxR was upregulated and appeared as a downstream target gene of Nrf2, suggesting that Nrf2 may be another pathogenesis factor of CML besides Ph chromosome [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>]. However, whether TrxR expression is also correlated with Nrf2 expression at both mRNA and protein levels in the imatinib-resistant K562 cells and the potential role of Nrf2 in conferring imatinib resistance to K562 cells have not been extensively elucidated so far.</p><p>In the present study, we investigate the effects of Nrf2 knockdown on drug resistance, ROS production, cell proliferation, and apoptosis, as well as the relationship between Nrf2 and TrxR expressions in imatinib-resistant K562/G01 cell line.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Cell Culture</title><p>Human CML K562 cell line was purchased from the cell bank of Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences (Shanghai, China). Imatinib-resistant CML K562/G01 cell line was purchased from the Institute of Hematology, Chinese Academy of Medical Sciences (Tianjin, China). K562 cells and K562/G01 cells were incubated in RPMI l640 medium containing 1% of penicillin and streptomycin and 10% fetal bovine serum (FBS) at 37°C under 5% CO<sub>2</sub> in saturated humidity.</p><p>Imatinib, friendly provided by Novartis AG (Basel, Switzerland), was dissolved into 10 mg/ml stock solution with dimethyl sulfoxide (DMSO) and was diluted with saline water before use. As previously described [<xref rid="B23" ref-type="bibr">23</xref>], 2 <italic>μ</italic>M imatinib was added in the culture medium to maintain the resistance of the K562/G0l cells, and the cells were cultured for 2 weeks in the absence of fungicide before experiments. Cell culture medium was changed every 1-2 days.</p></sec><sec id="sec2.2"><title>2.2. Establishment of Stable Cells with Knockdown of Nrf2</title><p>Four siRNA sequences (<xref rid="tab1" ref-type="table">Table 1</xref>) and one random negative control sequence (antisense strand sequence: 5′-TTCTCCGAACGTGTCACGT-3′) were cloned into the lentiviral vector pGCSIL-GFP with the U6-vshRNA-CMV-GFP frame. In terms of our previous experiment of Nrf2 knockdown in K562 [<xref rid="B21" ref-type="bibr">21</xref>], the most effective siRNA sequence (antisense strand sequence: 5′-TTGTGTTTAGTGAAATGCCGG-3′) with a targeting sequence located at 1586 locus of <italic>Nrf2</italic> gene (GenBank accession No. NM_006164.3) was selected in preexperiments (<xref rid="tab2" ref-type="table">Table 2</xref>). Lentiviral particles were produced in K562/G01 cells by transiently cotransfecting the control lentiviral vector (NC-GFP-LV) or Nrf2-knockdown lentiviral vector (Nrf2-RNAi-LV) together with helper plasmids pHelper 1.0 (Gag and Pol) and pHelper 2.0 (VSVG) using house-made transfection reagents from Shanghai Genechem Co., Ltd. (Shanghai, China). The vector constructions, verification by sequencing, virus packaging, and collection of the corresponding viral supernatants were performed by Shanghai Genechem Co., Ltd. (Shanghai, China).</p><p>K562/G0l cells in the logarithmic growth phase were inoculated on 24-well plates at a density of 5 × 10<sup>4</sup>/ml and cultured for 24 h until the confluence was around 50%. K562/G0l cells were divided into three groups: experiment group infected with Nrf2-RNAi-LV, control group infected with NC-GFP-LV, and uninfected blank group. Cells were infected by lentivirus with the best multiplicity of infection (MOI = 70) obtained in the preexperiments, and the culture medium was changed after 8 h.</p><p>A single green fluorescent protein- (GFP-) marked cell was obtained with the limited dilution method. Briefly, some single clones were identified microscopically after culturing for one week in 96-well plates and were translocated into 24-well plates for expansion. The infection efficiency was detected under a laser scanning confocal microscope (LSCM; Olympus, Tokyo, Japan) and by flow cytometry (FCM). The uninfected cells were used as negative controls for evaluating the infection efficiency. The stably-infected single clones were selected with three rounds of limited dilution.</p></sec><sec id="sec2.3"><title>2.3. Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR)</title><p>Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions, and RNA quality was confirmed by gel electrophoresis. Total RNA (1 <italic>μ</italic>g each sample) was used to synthesize cDNA utilizing the PrimeScript® RT Master Mix Perfect Real Time Reagent Kit (Takara Bio Inc., Shiga Prefecture, Japan). The cDNA was subjected to RT-qPCR using the SYBR® Premix Ex TaqTM II (Tli RNaseH Plus) Reagent Kit (TaKaRa Bio Inc.) and an AB7500 RT-PCR instrument (Applied Biosystems, Foster City, CA, USA). The PCR reaction protocol consisted of two steps: step 1, initial denaturation for 30 s at 95°C; step 2, denaturation for 5 s at 95°C, annealing and extension for 31 s at 60°C, and fluorescence signal acquisition. The reactions had a total of 40 cycles and ended with a melting curve which consisted of 15 s at 95°C, 1 min at 60°C, 15 s at 95°C, and 15 s at 60°C. PCR primer sequences used were listed in <xref rid="tab3" ref-type="table">Table 3</xref>. PCR primers were synthesized by Sangon Biotech Co. Ltd. (Shanghai, China). The experiments were repeated for 3 times and each sample was run in triplicates. PCR product specificity was confirmed by melting curve analysis. Gene expression levels were normalized to the internal control gene GAPDH and calculated with the 2<sup>−ΔΔCT</sup> method [<xref rid="B24" ref-type="bibr">24</xref>].</p></sec><sec id="sec2.4"><title>2.4. Western Blot Assay</title><p>Cells were harvested and sonicated in the RIPA (radioimmunoprecipitation assay) buffer for 0.5 h on ice. Then, cell lysates were centrifuged at 12,000 rpm at 4°C for 15 min. After collecting the supernatant, protein concentrations were determined with a BCA Reagent Kit (Thermo Fisher Scientific, Waltham, MA, USA). Proteins (30–50 <italic>µ</italic>g) were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose (NC) membranes. Membranes were blocked with 5% skim milk for 2 h at room temperature and incubated with primary antibodies against Nrf2 (1 : 200 dilution; Santa Cruz Biotechnology, Dallas, TX, USA), TrxR (1 : 200 dilution; Santa Cruz Biotechnology) and <italic>β</italic>-actin (1 : 200 dilution; Bioss Antibodies, Woburn, MA, USA) overnight at 4°C. After being washed by Tris-buffered saline with 0.5% Tween 20 (TBST), membranes were incubated with secondary antibody-horseradish-peroxidase-labeled goat anti-rabbit IgG (1 : 10,000 dilution; ZSGB-BIO, Beijing, China) for 2 h at room temperature. Proteins of interest were visualized using enhanced chemiluminescence kit (EMD Millipore, Burlington, MA, USA). The band intensities were quantified by densitometry with <italic>β</italic>-actin as an internal control using Quantity One image processing software (Bio-Rad Laboratories, Hercules, CA, USA). Western blots of all the experiments were repeated at least 3 times and one representative blotting result is shown for each experiment.</p></sec><sec id="sec2.5"><title>2.5. Reactive Oxygen Species (ROS) Analysis</title><p>Rhodamine 123 (Sigma-Aldrich, St. Louis, MO, USA) was used as the ROS trapping agent. Three groups of cells were incubated with 1 M DHR (dihydrorhodamine; Sigma-Aldrich, St. Louis, MO, USA) for 1 h, 6 h, and 24 h, respectively. Then, cells were collected and detected by flow cytometry (EPICS® ALTRA™ Flow Cytometer, Beckman Coulter, Inc., Brea, CA, USA). A total of 1 × 10<sup>4</sup> living cells were analyzed in each sample. The mean fluorescence intensity (MFI) of rhodamine 123 was calculated to indicate the levels of ROS.</p></sec><sec id="sec2.6"><title>2.6. Cell Proliferation Assay</title><p>Cells were inoculated on a 96-well plate (1 × 10<sup>4</sup> cells per well) and cultured for 24 h. Imatinib at the doses of 3 <italic>μ</italic>M, 6 <italic>μ</italic>M, 12 <italic>μ</italic>M, 24 <italic>μ</italic>M, and 48 <italic>μ</italic>M, or 0.1 <italic>μ</italic>M, 0.2 <italic>μ</italic>M, 0.4 <italic>μ</italic>M, 0.8 <italic>μ</italic>M and 1.6 <italic>μ</italic>M, was added to the culture medium of K562/G01 cells or K562 cells, respectively, and cells were further cultured for 72 h. Then, 10 <italic>μ</italic>l Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added into each well and cells were incubated for additional 1 h at 37°C. The optical density (OD) was determined at 450 nm with a plate reader.</p><p>The cell growth inhibitory ratio was calculated according to the formulas specified below, and the dose-response curve was obtained by plotting the cell growth inhibitory ratio at different concentrations. The drug's half inhibitory concentration (IC<sub>50</sub>) was calculated according to the linear regression equation, and then the drug resistance index (RI) was calculated. The calculations were as follows:</p><p>Cell growth inhibiting ratio = 100 − (test OD/nontreated OD) × 100, RI = IC<sub>50</sub> of drug resistant cell line/IC<sub>50</sub> of sensitive cell line.</p></sec><sec id="sec2.7"><title>2.7. Apoptosis Analysis by Flow Cytometry (FCM)</title><p>Cells were diluted and seeded on a 24-well plate (1 × 10<sup>5</sup> cells per well). After culturing for 12 h, cells were treated with imatinib (at a final concentration of 6 <italic>μ</italic>M or 20 <italic>μ</italic>M) for 28 h. Then, cells were collected to analyze the apoptosis ratio by FCM with an Annexin V-PE/propidium iodide (PI) Apoptosis Detection Kit (Nanjing KeyGen Biotech. Co. Ltd, Nanjing, China) according to the manufacturer's protocol. Briefly, after washing with PBS and the binding buffer for one time each, cells were stained with Annexin V/PI for 20 min at room temperature in dark. After washing with the binding buffer once, the labeled cells were detected immediately by a flow cytometer (FACSCalibur, BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed by the Kaluza software (Beckman Coulter Inc., Brea, CA, USA). The cells in early stages of apoptosis were Annexin V positive and PI negative, whereas the cells in the late stages of apoptosis were Annexin V and PI double positive.</p></sec><sec id="sec2.8"><title>2.8. Statistics</title><p>Data were analyzed by SPSS 20.0 (IBM, Armonk, NY, USA). All experiments were conducted at least three times, and data are expressed as means ± standard deviation (SD). The data with two groups of means were compared by <italic>t</italic>-test, while multiple groups of means were compared by one-way analysis of variance (ANOVA). The correlation between Nrf2 and TrxR expressions was analyzed by Pearson's correlation. Statistically significant difference was represented by <italic>p</italic> < 0.05.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Imatinib-Resistant K562/G01 Cell Line Demonstrates Higher Levels of Nrf2 Expression than the Parental K562 Cell Line</title><p>In order to determine the role of Nrf2 in imatinib resistance of CML, we first compared the expression levels of Nrf2 in the imatinib-sensitive cell line K562 and the imatinib-resistant cell line K562/G01 by RT-qPCR and western blot assays. As shown in <xref ref-type="fig" rid="fig1">Figure 1(a)</xref>, the expression level of Nrf2 mRNA was significantly higher (<italic>p</italic>=0.006) in K562/G01 cells (1.37 ± 0.05) than that in K562 cells (1.00 ± 0.08). Consistently, K562/G01 cells also demonstrated significantly higher expression of Nrf2 protein than the parental K562 cells (<italic>p</italic>=0.005) (Figures <xref ref-type="fig" rid="fig1">1(b)</xref> and <xref ref-type="fig" rid="fig1">1(c)</xref>). Therefore, Nrf2 is more expressed in the imatinib-resistant cell line K562/G01 at both transcription and protein levels, which supports our hypothesis that Nrf2 plays a role in imatinib resistance in K562/G01 cells.</p></sec><sec id="sec3.2"><title>3.2. Establishment and Verification of Stable GFP-Expressing K562/G01 Cells with Nrf2 Knockdown</title><p>We then sought out to establish a stable cell line with Nrf2 knockdown in K562/G01 cells by lentivirus infection. At 72 hours after infection, K562/G01 cells were green fluorescent positive under LSCM, indicating that the viral vector had been successfully delivered into cells. We adopted a limited dilution method to obtain single clones with stable infection. After the stably infected single clones were expanded, almost all the cells showed strong green fluorescence under LSCM (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>). As indicated by the percentages of GFP-positive cells, FCM assay also showed that the infection ratios of NC-GFP-LV control group and Nrf2-RNAi-LV group were (96.1 ± 1.3)% and (93.5 ± 3.8)%, respectively (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>).</p></sec><sec id="sec3.3"><title>3.3. Identification of a Positive Correlation between Nrf2 Expression and TrxR Expression in K562/G01 Cells</title><p>We verified the knock down efficiency of Nrf2 in the Nrf2-RNAi-LV-infected stable K562/G01 cells by RT-qPCR. As shown in <xref ref-type="fig" rid="fig3">Figure 3(a)</xref>, the relative expression levels of Nrf2 mRNA was 0.33 ± 0.09, 0.98 ± 0.44, and 0.98 ± 0.21 in Nrf2-RNAi-LV-infected group, NC-GFP-LV control group, and K562/G01 blank group, respectively. Compared with the NC-GFP-LV control group, Nrf2 mRNA was significantly (<italic>p</italic>=0.010) reduced (66.3 ± 0.42)% in the Nrf2-RNAi-LV-infected group. However, no statistical difference (<italic>p</italic>=0.989) on Nrf2 mRNA expression between uninfected K562/G01 cells and NC-GFP-LV control group was observed.</p><p>In our previous studies, we found that the TrxR activity of K562 cells was significantly higher than that of normal bone marrow mononuclear cells [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. After imatinib treatment, the expression levels of TrxR mRNA and protein significantly increased in CML patients than that in the MMR group. In addition, TrxR was overexpressed especially during the progression of CML (AP stage and BC stage) [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. Therefore, we checked whether TrxR was also expressed more in the imatinib-resistant K562/G01 cells. The expression of TrxR mRNA was 0.42 ± 0.13, 0.92 ± 0.44, and 1.01 ± 0.17 in the Nrf2-RNAi-LV-infected group, NC-GFP-LV control group, and K562/G01 blank group, respectively (<xref ref-type="fig" rid="fig3">Figure 3(b)</xref>). Indeed, K562/G01 cells with knockdown of Nrf2 also demonstrate lower expression levels of TrxR mRNA than the other two groups, with a statistical difference (<italic>p</italic>=0.034).</p><p>The expression level of Nrf2 protein was decreased ((65.82 ± 2.36)%) in the Nrf2-RNAi-LV-infected group, with a statistical difference (<italic>p</italic>=0.003), compared with that of the NC-GFP-LV control group and K562/G01 blank group. However, no difference (<italic>p</italic>=0.886) between the NC-GFP-LV control group and K562/G01 blank group was observed (Figures <xref ref-type="fig" rid="fig3">3(c)</xref> and <xref ref-type="fig" rid="fig3">3(d)</xref>). These results indicated that Nrf2-RNAi-LV could effectively knock down the expressions of Nrf2 protein in the K562/G01 cells, while NC-GFP-LV had no impact on the expression of Nrf2, which was in line with the RT-qPCR results. Similarly, TrxR protein also demonstrated a significantly lower expression level in the Nrf2-RNAi-LV-infected group than the other two groups, with a statistical difference (<italic>p</italic>=0.001), while no significant difference (<italic>p</italic>=0.933) between the NC-GFP-LV control group and K562/G01 blank group (Figures <xref ref-type="fig" rid="fig3">3(c)</xref> and <xref ref-type="fig" rid="fig3">3(e)</xref>).</p><p>Taken together, TrxR showed the same trend of reduced expression as Nrf2 after Nrf2-RNAi-LV infection in K562/G01 cells. Through analysis with Pearson's correlation, it was found that the expression of TrxR mRNA was positively correlated with that of Nrf2 mRNA (<italic>r</italic> = 0.498, <italic>p</italic>=0.036) among the three groups, and this correlation was also present in terms of the expression of TrxR protein among these groups (<italic>r</italic> = 0.998, <italic>p</italic>=0.041) (<xref rid="tab4" ref-type="table">Table 4</xref>).</p></sec><sec id="sec3.4"><title>3.4. Knockdown of Nrf2 in K562/G01 Cells Increases the ROS Level</title><p>The ROS levels in cell lines of the three groups were detected at three time points of 1 h, 6 h, and 24 h after incubating with dihydrorhodamine, separately. The mean fluorescence intensities of ROS staining in Nrf2-RNAi-LV-infected group were 2.31 ± 0.16, 7.04 ± 0.14, and 40.43 ± 0.78 at 1 h, 6 h, and 24 h, respectively. These values were 1.92 ± 0.05, 5.53 ± 0.10, and 25.20 ± 1.35 in the NC-GFP-LV control group and 1.55 ± 0.21, 4.10 ± 0.05, and 21.95 ± 1.46 in the blank group at 1 h, 6 h, and 24 h, respectively. The Nrf2-RNAi-LV-infected group showed a higher ROS level than that in the other two groups at the same time points with a statistically significant difference (<italic>p</italic>=0.009, 0.001, and 0.001 at 1 h, 6 h, and 24 h, respectively), and no differences between the blank group and NC-GFP-LV control group (<italic>p</italic>=0.056, 0.051, and 0.059 at 1 h, 6 h, and 24 h, respectively) were observed (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>The mean fluorescence intensities (MFIs) of ROS staining by Rhodamine 123 in the indicated cell lines were detected after cells were incubated with 1 mol/L DHR for 1 h, 6 h, and 24 h, respectively. <italic>n</italic> = 3 for each group; <sup><italic>∗</italic></sup><italic>p</italic> < 0.05, compared with the control group and the blank K562/G01 cells group.</p></sec><sec id="sec3.5"><title>3.5. Knockdown of Nrf2 Sensitizes K562/G01 Cells to Imatinib Treatments</title><p>To substantiate the role of Nrf2 in imatinib resistance, we determined the IC<sub>50</sub> and RI of parental K562 cells and K562/G01 cells with varied expression levels of Nrf2. Firstly, we identified that the IC<sub>50</sub> value of K562 cells and K562/G01 cells was 0.663 <italic>μ</italic>mol/L and 22.64 <italic>μ</italic>mol/L, respectively, as measured by the CCK-8 method, and the RI of K562/G01 cells was calculated as 34.28. Knocking down of Nrf2 with siRNA significantly increased the sensitivity of K562/G01 cells to imatinib treatments. The results showed that the IC<sub>50</sub> of NC-GFP-LV control group and Nrf2-RNAi-LV-infected group was 21.37 <italic>μ</italic>mol/L and 14.64 <italic>μ</italic>mol/L, respectively, and RIs were 32.23 and 22.09, respectively, which suggested that the knockdown of Nrf2 significantly decreased the IC<sub>50</sub> and RI in K562/G01 cells. As expected, there was no significant difference between the uninfected K562/G01 group and the NC-GFP-LV control group in terms of IC<sub>50</sub> and RI. The cellular proliferative inhibition ratio in the Nrf2-RNAi-LV-infected group was significantly higher than that in the control group and the blank group at a concentration of imatinib except that with 3 <italic>μ</italic>M (<italic>p</italic>=0.101, 0.010, 0.002, 0.001, and 0.025 at 3 <italic>μ</italic>M, 6 <italic>μ</italic>M, 12 <italic>μ</italic>M, 24 <italic>μ</italic>M, and 48 <italic>μ</italic>M, respectively). However, there was no difference in the control group and the blank group at all concentration of imatinib (<italic>p</italic>=0.755, 0.628, 0.278, 0.558, and 0.826 at 3 <italic>μ</italic>M, 6 <italic>μ</italic>M, 12 <italic>μ</italic>M, 24 <italic>μ</italic>M, and 48 <italic>μ</italic>M, respectively) (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>The percentages of cellular proliferation inhibition ratio were calculated in the indicated cell lines after treatments with 3 <italic>μ</italic>M, 6 <italic>μ</italic>M, 12 <italic>μ</italic>M, 24 <italic>μ</italic>M, and 48 <italic>μ</italic>M imatinib for 72 hours. Cell proliferation was accessed with the CCK-8 method. <italic>n</italic> = 3 for each group; <sup><italic>∗</italic></sup><italic>p</italic> < 0.05, compared with the control group and the blank K562/G01 cells group.</p></sec><sec id="sec3.6"><title>3.6. Knockdown of Nrf2 Significantly Increases the Apoptosis Ratio of K562/G01 Cells after Imatinib Treatments</title><p>To further confirm that the K562/G01 cells with Nrf2 knockdown were more sensitive to imatinib treatments, we determined the apoptosis ratio of K562/G01 cells with varied expression levels of Nrf2 after treating with 6 <italic>μ</italic>mol/L or 20 <italic>μ</italic>mol/L imatinib by flow cytometry (<xref ref-type="fig" rid="fig6">Figure 6(a)</xref>). Without imatinib treatments, the apoptosis ratios were (0.86 ± 0.51)%, (0.87 ± 0.41)%, and (0.98 ± 0.41)% in the Nrf2-RNAi-LV experimental group, NC-GFP-LV control group, and blank group, respectively. After treating with imatinib at 6 <italic>μ</italic>mol/L and 20 <italic>μ</italic>mol/L, the apoptosis ratios were (10.58 ± 1.82)% and (34.46 ± 1.99)% in the Nrf2-RNAi-LV-infected group, (5.04 ± 0.83)% and (20.09 ± 2.06)% in the NC-GFP-LV control group, and (5.18 ± 0.9)% and (19.86 ± 2.22)% in the blank group, respectively (<xref ref-type="fig" rid="fig6">Figure 6(b)</xref>). Apoptosis ratio was significantly higher (<italic>p</italic>=0.007 and 0.001 at 6 <italic>μ</italic>mol/L and 20 <italic>μ</italic>mol/L, respectively) in the Nrf2-RNAi-LV-infected group than that in other two groups regardless of the imatinib concentration, while there was no difference between the apoptosis ratios in blank control K562/G01 cells and NC-GFP-LV control group (<italic>p</italic>=0.916 and 0.917 at 6 <italic>μ</italic>mol/L and 20 <italic>μ</italic>mol/L, respectively) (<xref ref-type="fig" rid="fig6">Figure 6(b)</xref>).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>It has been reported that Nrf2 inducer can increase resistance to imatinib in K562 cells, suggesting that Nrf2 is involved in imatinib resistance of CML [<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>]. In the present study, we used the imatinib-resistant BCR/ABL<sup>+</sup> cell line K562/G01 to investigate the role of Nrf2 in conferring imatinib resistance in CML. We found that K562/G01 cells have higher levels of Nrf2 expression than the parental K562 cells. However, the mechanism that controls Nrf2 expression in drug resistance of CML is presently unknown due to the complex cross-talks between Nrf2 and many other signaling pathways. In addition, the stable K562/G01 cell line with knockdown of Nrf2 was established after siRNA-expressing lentivirus infection of parental cells, and a positive correlation between Nrf2 expression and TrxR expression was observed [<xref rid="B21" ref-type="bibr">21</xref>]. Knockdown of Nrf2 in K562/G01 cells increased the ROS level and sensitized the cells to imatinib treatments. We conclude that the expression of Nrf2, in conjunction with TrxR expression, is involved in imatinib resistance of CML and the Nrf2-TrxR axis could be used as a therapy target for imatinib-resistant CML.</p><p>The molecular mechanisms for the relationship between TrxR and Nrf2 are likely complex and multifaceted. Over the years, various reports on the relationship between Nrf2 and TrxR have been inconsistent: whether TrxR synergizes with Nrf2 or attenuates the roles of Nrf2 seems to be case-dependent. Cebula et al. summarized that TrxR may be viewed as a potent Nrf2 regulator and gatekeeper of Nrf2 activation [<xref rid="B27" ref-type="bibr">27</xref>], whereas someone reported loss of TrxR activity can signal Nrf2 activation without a general oxidative stress. TrxR can be directly inhibited by high ROS levels through an oligomerization process. In multiple myeloma cells, TrxR inhibition induces HO-1 expression through the Nrf2 accumulation transcriptional machinery simultaneously and significantly increased intracellular ROS levels [<xref rid="B28" ref-type="bibr">28</xref>]. In our previous studies, we found that despite achieving complete remission in AML or MMR in CML, the expression of TrxR was still higher than normal [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B29" ref-type="bibr">29</xref>]. After knockdown of Nrf2 in K562 cell line, TrxR was decreased synchronously [<xref rid="B21" ref-type="bibr">21</xref>]. In this study, we confirmed that the levels of TrxR mRNA and protein were decreased in concert with Nrf2 in K562/G01 cells infected with Nrf2-RNAi-LV lentivirus. Therefore, it appeared that TrxR, as one of Nrf2 target genes, was coordinated with Nrf2 to be involved in the drug resistance of CML. It is worth noting that the TrxR system not only controls intracellular ROS levels and redox events but also itself is regulated by redox processes, leading to the potential for autoregulatory loops. Therefore, the mechanisms between Nrf2 and TrxR in CML and imatinib-resistant CML are likely to be complex, and the effects of various factors may be different depending on the cell environment and redox state.</p><p>ROS and oxidative stress have long been associated with cancer [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. Accumulating evidence supports that ROS are bifaceted in cellular processes. Modest levels of ROS are required for cancer cells to survive, whereas excessive levels destroy them [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. In our study, the intracellular ROS significantly increased in a time-dependent mode in infected K562/G01 cell line with Nrf2 knockdown and TrxR decreasing, although ROS also increased with time in the uninfected group attributed to BCR-ABL constitutively producing intracellular ROS [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. It is reported that increased activity of antioxidant genes by Nrf2 in cancer cells can repress p53-dependent apoptosis; the latter requires the accumulation of ROS, oppositely, the loss of Nrf2 increases ROS [<xref rid="B34" ref-type="bibr">34</xref>]. In multiple myeloma, intracellular ROS levels are increased when TrxR is restrained [<xref rid="B35" ref-type="bibr">35</xref>]. Nrf2 may also regulate sensitivity to ROS-producing therapeutic agents [<xref rid="B6" ref-type="bibr">6</xref>]. Therefore, we speculated that the downregulation of Nrf2 and TrxR may lead to inhibition of their biological activity, compromised ability as the cellular antioxidant or cause increased level of intracellular ROS to promote the apoptosis of K562/G01. However, whether this elevated ROS can continue to eradicate CML cells is warranted. Moreover, how to define and weigh the effect of the production of ROS on imatinib resistance of CML is challenging.</p><p>The IC<sub>50</sub> value of imatinib for K562/G01 cells was about 31.14-fold higher than that of K562, suggesting that K562/G01 cells had acquired significant resistance to imatinib. Knocking down of Nrf2 increased the sensitivity of K562/G01 cells to imatinib and the drug resistance index decreased. The K562/G01 cell line is an imatinib-resistant cell line established by inducing the K562 cell line by low doses of imatinib, but it has no BCR/ABL gene mutation [<xref rid="B23" ref-type="bibr">23</xref>]. Therefore, the present results indicated that Nrf2 was involved in imatinib resistance of K562/G01 with independence of BCR-ABL. Other studies also have found that Nrf2 knockdown in the resistant cells can increase the sensitivity of tumor cells to chemotherapeutic agents. For example, the silencing Nrf2 can increase the sensitivity of cisplatin-resistant ovarian cancer cell strain to cisplatin and that of lung cancer cells to doxorubicin [<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>]. Similar reports also presented in studies involving gallbladder cancer and colon cancer [<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>].</p><p>In the present study, the apoptosis ratios were similarly low in both the infected and noninfected groups when Nrf2 was knockdown. Apoptosis was significantly increased in the infected group in a dose-dependent manner after cells were treated with imatinib. Recent studies have demonstrated that Nrf2 acts as a dual role in cancers: it protects the survival of benign from chemical carcinogenesis and environmental stresses, whereas it provides advantages for the development of cancer cells [<xref rid="B40" ref-type="bibr">40</xref>]. Probably, this is the reason for no significant difference in apoptosis rates between the infected and the noninfected group. In the infected group, the increase in apoptosis rate was mainly caused by the addition of imatinib, suggesting that the sensitivity of the infected group to imatinib was restored after Nrf2 gene knockdown. Collectively, our data suggest that Nrf2 expression confers imatinib resistance to K562/G01 cells.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>In summary, our <italic>in vitro</italic> preliminary study confirms that Nrf2 expression is a key factor of resistance to imatinib in K562/G01 cell lineage with independence of BCR-ABL mutation. Downregulating Nrf2 expression in K562/G01 cells was companied with TrxR decreasing, which promoted imatinib-induced apoptosis, suppressed cell proliferation, and enhanced the intracellular ROS level to activate oxidation stress system in K562/G01 cells. Although in lack of <italic>in vivo</italic> animal studies and clinical data, our work indicates that the Nrf2-TrxR axis is a potential target for reversing the drug resistance in CML. How to smoothly transfer its functions between normal cells and tumor cells to achieve the cytoprotection of normal cells and maintaining of anti-tumor effects is more complex. Therefore, it will be necessary to understand the molecular regulations of Nrf2/TrxR and identify the individualized status of Nrf2/TrxR expression in imatinib-resistant CML.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by grants from the Natural Science Foundation of Shanxi (grant no. 2012011038-5) and Shanxi Medical and Health Science and Technology Plan Project (grant no. 20100202).</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>The data set supporting the results of this article are included within the article.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flis</surname><given-names>S.</given-names></name><name><surname>Chojnacki</surname><given-names>T.</given-names></name></person-group><article-title>Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities</article-title><source><italic toggle="yes">Drug Design, Development and Therapy</italic></source><year>2019</year><volume>13</volume><fpage>825</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.2147/dddt.s191303</pub-id><pub-id pub-id-type="other">2-s2.0-85063296599</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stagno</surname><given-names>F.</given-names></name><name><surname>Stella</surname><given-names>S.</given-names></name><name><surname>Spitaleri</surname><given-names>A.</given-names></name><name><surname>Pennisi</surname><given-names>M. S.</given-names></name><name><surname>Di Raimondo</surname><given-names>F.</given-names></name><name><surname>Vigneri</surname><given-names>P.</given-names></name></person-group><article-title>Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes</article-title><source><italic toggle="yes">Expert Review of Anticancer Therapy</italic></source><year>2016</year><volume>16</volume><issue>3</issue><fpage>273</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1586/14737140.2016.1151356</pub-id><pub-id pub-id-type="other">2-s2.0-84959359551</pub-id><pub-id pub-id-type="pmid">26852913</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milojkovic</surname><given-names>D.</given-names></name><name><surname>Apperley</surname><given-names>J.</given-names></name></person-group><article-title>Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2009</year><volume>15</volume><issue>24</issue><fpage>7519</fpage><lpage>7527</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.ccr-09-1068</pub-id><pub-id pub-id-type="other">2-s2.0-73349097214</pub-id><pub-id pub-id-type="pmid">20008852</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>T.</given-names></name><name><surname>Tyndel</surname><given-names>M. S.</given-names></name><name><surname>Kim</surname><given-names>H. J.</given-names></name><etal></etal></person-group><article-title>Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy</article-title><source><italic toggle="yes">Blood</italic></source><year>2017</year><volume>129</volume><issue>1</issue><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-04-708560</pub-id><pub-id pub-id-type="other">2-s2.0-85014909859</pub-id><pub-id pub-id-type="pmid">27733357</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soverini</surname><given-names>S.</given-names></name><name><surname>Mancini</surname><given-names>M.</given-names></name><name><surname>Bavaro</surname><given-names>L.</given-names></name><name><surname>Cavo</surname><given-names>M.</given-names></name><name><surname>Martinelli</surname><given-names>G.</given-names></name></person-group><article-title>Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy</article-title><source><italic toggle="yes">Molecular Cancer</italic></source><year>2018</year><volume>17</volume><issue>1</issue><fpage>p. 49</fpage><pub-id pub-id-type="doi">10.1186/s12943-018-0780-6</pub-id><pub-id pub-id-type="other">2-s2.0-85042164288</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>K.</given-names></name><name><surname>Wakabayashi</surname><given-names>N.</given-names></name><name><surname>Katoh</surname><given-names>Y.</given-names></name><etal></etal></person-group><article-title>Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain</article-title><source><italic toggle="yes">Genes & Development</italic></source><year>1999</year><volume>13</volume><issue>1</issue><fpage>76</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1101/gad.13.1.76</pub-id><pub-id pub-id-type="other">2-s2.0-0032953192</pub-id><pub-id pub-id-type="pmid">9887101</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>C. A.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Manevich</surname><given-names>Y.</given-names></name></person-group><article-title>Peroxiredoxin 1 and its role in cell signaling</article-title><source><italic toggle="yes">Cell Cycle</italic></source><year>2009</year><volume>8</volume><issue>24</issue><fpage>4072</fpage><lpage>4078</lpage><pub-id pub-id-type="doi">10.4161/cc.8.24.10242</pub-id><pub-id pub-id-type="other">2-s2.0-74849098583</pub-id><pub-id pub-id-type="pmid">19923889</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdul-Aziz</surname><given-names>A.</given-names></name><name><surname>MacEwan</surname><given-names>D. J.</given-names></name><name><surname>Bowles</surname><given-names>K. M.</given-names></name><name><surname>Rushworth</surname><given-names>S. A.</given-names></name></person-group><article-title>Oxidative stress responses and NRF2 in human leukaemia</article-title><source><italic toggle="yes">Oxidative Medicine and Cellular Longevity</italic></source><year>2015</year><volume>2015</volume><fpage>7</fpage><pub-id pub-id-type="publisher-id">454659</pub-id><pub-id pub-id-type="doi">10.1155/2015/454659</pub-id><pub-id pub-id-type="other">2-s2.0-84928412324</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radwan</surname><given-names>S. M.</given-names></name><name><surname>Hamdy</surname><given-names>N. M.</given-names></name><name><surname>Hegab</surname><given-names>H. M.</given-names></name><name><surname>El-Mesallamy</surname><given-names>H. O.</given-names></name></person-group><article-title>Beclin-1 and hypoxia-inducible factor-1<italic>α</italic> genes expression: potential biomarkers in acute leukemia patients</article-title><source><italic toggle="yes">Cancer Biomarkers</italic></source><year>2016</year><volume>16</volume><issue>4</issue><fpage>619</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.3233/cbm-160603</pub-id><pub-id pub-id-type="other">2-s2.0-84965017134</pub-id><pub-id pub-id-type="pmid">27002764</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhumina</surname><given-names>A.</given-names></name><name><surname>Pogossyan</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><etal></etal></person-group><article-title>Nrf2 expression in CML and AML patients’ peripheral blood mononuclear cells treated by vitamin D, carnosic acid and curcumin</article-title><source><italic toggle="yes">Journal of Pure and Applied Microbiology</italic></source><year>2018</year><volume>12</volume><issue>2</issue><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.22207/jpam.12.2.04</pub-id><pub-id pub-id-type="other">2-s2.0-85052552277</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>P.</given-names></name><name><surname>Ren</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><etal></etal></person-group><article-title>The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes</article-title><source><italic toggle="yes">Haematologica</italic></source><year>2019</year><volume>104</volume><issue>3</issue><fpage>485</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.3324/haematol.2018.197749</pub-id><pub-id pub-id-type="pmid">30262569</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Meng</surname><given-names>L.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Xin</surname><given-names>Y.</given-names></name></person-group><article-title>Anticancer activity of sulforaphane: the epigenetic mechanisms and the Nrf2 signaling pathway</article-title><source><italic toggle="yes">Oxidative Medicine and Cellular Longevity</italic></source><year>2018</year><volume>2018</volume><fpage>10</fpage><pub-id pub-id-type="publisher-id">5438179</pub-id><pub-id pub-id-type="doi">10.1155/2018/5438179</pub-id><pub-id pub-id-type="other">2-s2.0-85051117029</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Jin</surname><given-names>J.</given-names></name></person-group><article-title>Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters</article-title><source><italic toggle="yes">Drug Metabolism Reviews</italic></source><year>2016</year><volume>48</volume><issue>4</issue><fpage>541</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1080/03602532.2016.1197239</pub-id><pub-id pub-id-type="other">2-s2.0-84991107767</pub-id><pub-id pub-id-type="pmid">27320238</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rushworth</surname><given-names>S. A.</given-names></name><name><surname>Macewan</surname><given-names>D. J.</given-names></name></person-group><article-title>The role of Nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells</article-title><source><italic toggle="yes">Cancers</italic></source><year>2011</year><volume>3</volume><issue>2</issue><fpage>1605</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.3390/cancers3021605</pub-id><pub-id pub-id-type="other">2-s2.0-79959693771</pub-id><pub-id pub-id-type="pmid">24212776</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rushworth</surname><given-names>S. A.</given-names></name><name><surname>Zaitseva</surname><given-names>L.</given-names></name><name><surname>Murray</surname><given-names>M. Y.</given-names></name><name><surname>Shah</surname><given-names>N. M.</given-names></name><name><surname>Bowles</surname><given-names>K. M.</given-names></name><name><surname>MacEwan</surname><given-names>D. J.</given-names></name></person-group><article-title>The high Nrf2 expression in human acute myeloid leukemia is driven by NF-<italic>κ</italic>B and underlies its chemo-resistance</article-title><source><italic toggle="yes">Blood</italic></source><year>2012</year><volume>120</volume><issue>26</issue><fpage>5188</fpage><lpage>5198</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-04-422121</pub-id><pub-id pub-id-type="other">2-s2.0-84871519753</pub-id><pub-id pub-id-type="pmid">23077289</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karathedath</surname><given-names>S.</given-names></name><name><surname>Rajamani</surname><given-names>B. M.</given-names></name><name><surname>Aalam</surname><given-names>S. M. M.</given-names></name><etal></etal></person-group><article-title>Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2017</year><volume>12</volume><issue>5</issue><pub-id pub-id-type="publisher-id">e0177227</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0177227</pub-id><pub-id pub-id-type="other">2-s2.0-85019486203</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal></etal></person-group><article-title>Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-kappaB inactivation</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2017</year><volume>7</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/srep39950</pub-id><pub-id pub-id-type="other">2-s2.0-85011356970</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Fang</surname><given-names>J.</given-names></name></person-group><article-title>Targeting the thioredoxin system for cancer therapy</article-title><source><italic toggle="yes">Trends in Pharmacological Sciences</italic></source><year>2017</year><volume>38</volume><issue>9</issue><fpage>794</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2017.06.001</pub-id><pub-id pub-id-type="other">2-s2.0-85021149965</pub-id><pub-id pub-id-type="pmid">28648527</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamal</surname><given-names>A. M.</given-names></name><name><surname>El-Hefny</surname><given-names>N. H.</given-names></name><name><surname>Hegab</surname><given-names>H. M.</given-names></name><name><surname>El-Mesallamy</surname><given-names>H. O.</given-names></name></person-group><article-title>Expression of thioredoxin-1 (TXN) and its relation with oxidative DNA damage and treatment outcome in adult AML and ALL: a comparative study</article-title><source><italic toggle="yes">Hematology</italic></source><year>2016</year><volume>21</volume><issue>10</issue><fpage>567</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1080/10245332.2016.1173341</pub-id><pub-id pub-id-type="other">2-s2.0-84978499812</pub-id><pub-id pub-id-type="pmid">27158980</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J. J.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Wei</surname><given-names>H. L.</given-names></name><name><surname>Yi</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>H. S.</given-names></name><name><surname>Gao</surname><given-names>L. P.</given-names></name></person-group><article-title>Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells</article-title><source><italic toggle="yes">Die Pharmazie</italic></source><year>2011</year><volume>66</volume><issue>6</issue><fpage>440</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">21699084</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>L. R.</given-names></name><name><surname>Wang</surname><given-names>H. W.</given-names></name><etal></etal></person-group><article-title>Effect of Nrf2 and TrxR on proliferation of chronic myeloid leukemia cell and its mechanism</article-title><source><italic toggle="yes">Zhonghua Xue Ye Xue Za Zhi</italic></source><year>2013</year><volume>34</volume><issue>6</issue><fpage>p. 527</fpage></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>L. R.</given-names></name><name><surname>Wang</surname><given-names>H. W.</given-names></name><name><surname>Zhu</surname><given-names>M. X.</given-names></name></person-group><article-title>Expression of nuclear factor erythroid-2 related factor 2 in chronic myeloid leukemia and its correlation with thioredoxin reductase</article-title><source><italic toggle="yes">Journal of Leukemia and Lymphoma</italic></source><year>2012</year><volume>21</volume><issue>9</issue><fpage>520</fpage><lpage>523</lpage></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Gu</surname><given-names>Z. L.</given-names></name><name><surname>Liang</surname><given-names>Z. Q.</given-names></name><name><surname>Yang</surname><given-names>C. Z.</given-names></name></person-group><article-title>Establishment of an imatinib resistant cell line K562/G01 and its characterization</article-title><source><italic toggle="yes">Zhonghua Xue Ye Xue Za Zhi</italic></source><year>2004</year><volume>25</volume><issue>6</issue><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">15308010</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>K. J.</given-names></name><name><surname>Schmittgen</surname><given-names>T. D.</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>−ΔΔCT</sup> method</article-title><source><italic toggle="yes">Methods</italic></source><year>2001</year><volume>25</volume><issue>4</issue><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="other">2-s2.0-0035710746</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonovolias</surname><given-names>I. D.</given-names></name><name><surname>Tsiftsoglou</surname><given-names>A. S.</given-names></name></person-group><article-title>Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells</article-title><source><italic toggle="yes">Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics</italic></source><year>2009</year><volume>17</volume><issue>11-12</issue><fpage>535</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.3727/096504009789745557</pub-id><pub-id pub-id-type="other">2-s2.0-70350485007</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>T.</given-names></name><name><surname>Kikuchi</surname><given-names>S.</given-names></name><name><surname>Ohmine</surname><given-names>K.</given-names></name><etal></etal></person-group><article-title>Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2</article-title><source><italic toggle="yes">Journal of Cellular Biochemistry</italic></source><year>2008</year><volume>104</volume><issue>2</issue><fpage>680</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1002/jcb.21659</pub-id><pub-id pub-id-type="other">2-s2.0-43449139414</pub-id><pub-id pub-id-type="pmid">18172853</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cebula</surname><given-names>M.</given-names></name><name><surname>Schmidt</surname><given-names>E. E.</given-names></name><name><surname>Arnér</surname><given-names>E. S. J.</given-names></name></person-group><article-title>TrxR1 as a potent regulator of the Nrf2-Keap1 response system</article-title><source><italic toggle="yes">Antioxidants & Redox Signaling</italic></source><year>2015</year><volume>23</volume><issue>10</issue><fpage>823</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1089/ars.2015.6378</pub-id><pub-id pub-id-type="other">2-s2.0-84936960918</pub-id><pub-id pub-id-type="pmid">26058897</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raninga</surname><given-names>P. V.</given-names></name><name><surname>Di Trapani</surname><given-names>G.</given-names></name><name><surname>Vuckovic</surname><given-names>S.</given-names></name><name><surname>Tonissen</surname><given-names>K. F.</given-names></name></person-group><article-title>Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma</article-title><source><italic toggle="yes">Redox Biology</italic></source><year>2016</year><volume>8</volume><fpage>175</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2016.01.007</pub-id><pub-id pub-id-type="other">2-s2.0-84954328137</pub-id><pub-id pub-id-type="pmid">26795735</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>L. R.</given-names></name><name><surname>Zhu</surname><given-names>M. X.</given-names></name><name><surname>Pan</surname><given-names>F.</given-names></name></person-group><article-title>Expression of thioredoxin reductase in myeloid leukemia and its significance</article-title><source><italic toggle="yes">Cancer Research and Clinic</italic></source><year>2013</year><volume>25</volume><fpage>223</fpage><lpage>226</lpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renschler</surname><given-names>M. F.</given-names></name></person-group><article-title>The emerging role of reactive oxygen species in cancer therapy</article-title><source><italic toggle="yes">European Journal of Cancer</italic></source><year>2004</year><volume>40</volume><issue>13</issue><fpage>1934</fpage><lpage>1940</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2004.02.031</pub-id><pub-id pub-id-type="other">2-s2.0-4143066896</pub-id><pub-id pub-id-type="pmid">15315800</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toler</surname><given-names>S. M.</given-names></name><name><surname>Noe</surname><given-names>D.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name></person-group><article-title>Selective enhancement of cellular oxidative stress by chloroquine: implications for the treatment of glioblastoma multiforme</article-title><source><italic toggle="yes">Neurosurgical Focus</italic></source><year>2006</year><volume>21</volume><issue>6</issue><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.3171/foc.2006.21.6.1</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sattler</surname><given-names>M.</given-names></name><name><surname>Verma</surname><given-names>S.</given-names></name><name><surname>Shrikhande</surname><given-names>G.</given-names></name><etal></etal></person-group><article-title>The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells</article-title><source><italic toggle="yes">Journal of Biological Chemistry</italic></source><year>2000</year><volume>275</volume><issue>32</issue><fpage>24273</fpage><lpage>24278</lpage><pub-id pub-id-type="doi">10.1074/jbc.m002094200</pub-id><pub-id pub-id-type="other">2-s2.0-0034637599</pub-id><pub-id pub-id-type="pmid">10833515</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Chu</surname><given-names>S. C.</given-names></name><name><surname>Gramlich</surname><given-names>J. L.</given-names></name><etal></etal></person-group><article-title>Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species</article-title><source><italic toggle="yes">Blood</italic></source><year>2005</year><volume>105</volume><issue>4</issue><fpage>1717</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-03-0849</pub-id><pub-id pub-id-type="other">2-s2.0-20844448882</pub-id><pub-id pub-id-type="pmid">15486067</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>No</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>Y. B.</given-names></name><name><surname>Song</surname><given-names>Y. S.</given-names></name></person-group><article-title>Targeting nrf2 signaling to combat chemoresistance</article-title><source><italic toggle="yes">Journal of Cancer Prevention</italic></source><year>2014</year><volume>19</volume><issue>2</issue><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.15430/jcp.2014.19.2.111</pub-id><pub-id pub-id-type="pmid">25337579</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raninga</surname><given-names>P. V.</given-names></name><name><surname>Di Trapani</surname><given-names>G.</given-names></name><name><surname>Vuckovic</surname><given-names>S.</given-names></name><name><surname>Bhatia</surname><given-names>M.</given-names></name><name><surname>Tonissen</surname><given-names>K. F.</given-names></name></person-group><article-title>Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma</article-title><source><italic toggle="yes">Oncotarget</italic></source><year>2015</year><volume>6</volume><issue>17</issue><fpage>15410</fpage><lpage>15424</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3795</pub-id><pub-id pub-id-type="other">2-s2.0-84934287525</pub-id><pub-id pub-id-type="pmid">25945832</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>J. M.</given-names></name><name><surname>Manandhar</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>H. R.</given-names></name><name><surname>Park</surname><given-names>H. M.</given-names></name><name><surname>Kwak</surname><given-names>M. K.</given-names></name></person-group><article-title>Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance</article-title><source><italic toggle="yes">Cancer Letters</italic></source><year>2008</year><volume>260</volume><issue>1-2</issue><fpage>96</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2007.10.022</pub-id><pub-id pub-id-type="other">2-s2.0-38149003106</pub-id><pub-id pub-id-type="pmid">18036733</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name></person-group><article-title>Expression and significance of Nrf2 and its target genes in pulmonary adenocarcinoma A549 cells resistant to cisplatin</article-title><source><italic toggle="yes">Chinese Journal of Lung Cancer</italic></source><year>2009</year><volume>12</volume><issue>11</issue><fpage>1150</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">20723361</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>T.</given-names></name><name><surname>Kokubu</surname><given-names>A.</given-names></name><name><surname>Gotoh</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer</article-title><source><italic toggle="yes">Gastroenterology</italic></source><year>2008</year><volume>135</volume><issue>4</issue><fpage>1358</fpage><lpage>1368.e4</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.06.082</pub-id><pub-id pub-id-type="other">2-s2.0-53049105119</pub-id><pub-id pub-id-type="pmid">18692501</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhdar</surname><given-names>H.</given-names></name><name><surname>Loyer</surname><given-names>P.</given-names></name><name><surname>Rauch</surname><given-names>C.</given-names></name><name><surname>Corlu</surname><given-names>A.</given-names></name><name><surname>Guillouzo</surname><given-names>A.</given-names></name><name><surname>Morel</surname><given-names>F.</given-names></name></person-group><article-title>Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells</article-title><source><italic toggle="yes">European Journal of Cancer</italic></source><year>2009</year><volume>45</volume><issue>12</issue><fpage>2219</fpage><lpage>2227</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2009.05.017</pub-id><pub-id pub-id-type="other">2-s2.0-67650922529</pub-id><pub-id pub-id-type="pmid">19524433</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X. J.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Villeneuve</surname><given-names>N. F.</given-names></name><etal></etal></person-group><article-title>Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2</article-title><source><italic toggle="yes">Carcinogenesis</italic></source><year>2008</year><volume>29</volume><issue>6</issue><fpage>1235</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgn095</pub-id><pub-id pub-id-type="other">2-s2.0-46949099638</pub-id><pub-id pub-id-type="pmid">18413364</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Imatinib-resistant K562/G01 cells had higher levels of Nrf2 expression than the parental K562 cells. (a) The expression levels of Nrf2 mRNA in K562/G01 cells and K562 cells were quantitated by RT-qPCR. (b, c) The expression levels of Nrf2 protein in K562/G01 cells and K562 cells were evaluated by western blot assays. The representative images showed the bands of Nrf2 protein, and <italic>β</italic>-actin was taken as an internal control (b). The relative expression level of Nrf2 protein was quantitated by calculating the densitometry of targeted bands (c). <italic>n</italic> = 3 for each group; <sup><italic>∗</italic></sup><italic>p</italic> < 0.05, compared between the indicated two cell lines.</p></caption><graphic xlink:href="BMRI2019-6502793.001"></graphic></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Verification of virus infection efficiency by monitoring GFP expression in K562/G01 cells. (a) Representative images of K562/G01 cells infected with Nrf2-RNAi-LV virus at 488 nm of the nominal optical excitation. Left: merged fluorescent images; middle: FITC fluorescent images; right: transmission photomicrograph at the bright light. Magnification, 10x. (b) Representative histogram plots showed the percentages of GFP-positive cells in uninfected blank K562/G01 cells, NC-GFP-LV-infected cells, and Nrf2-RNAi-LV-infected cells.</p></caption><graphic xlink:href="BMRI2019-6502793.002"></graphic></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Identification of a positive correlation between Nrf2 expression and TrxR expression in K562/G01 cells. (a, b) The expression levels of Nrf2 mRNA (a) and TrxR mRNA (b) were quantitated in the indicated cells by RT-qPCR. K562/G01, uninfected blank K562/G01 cells; NC-GFP-LV, NC-GFP-LV lentivirus-infected stable K562/G01 cells; Nrf2-RNAi-LV, Nrf2-RNAi-LV lentivirus-infected stable K562/G01 cells. (c–e) The expression levels of Nrf2 protein and TrxR protein were quantitated in the indicated cells by western blot. The representative images showed the bands of targeted proteins, and <italic>β</italic>-actin was taken as an internal control (c). The relative expression levels of Nrf2 protein (d) and TrxR protein (e) were quantitated by calculating the densitometry of targeted bands. <italic>n</italic> = 3 for each group; <sup><italic>∗</italic></sup><italic>p</italic> < 0.05, compared with the blank K562/G01 cells group.</p></caption><graphic xlink:href="BMRI2019-6502793.003"></graphic></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Knockdown of Nrf2 in K562/G01 cells increased the ROS level.</p></caption><graphic xlink:href="BMRI2019-6502793.004"></graphic></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Knockdown of Nrf2-sensitized K562/G01 cells to imatinib treatments.</p></caption><graphic xlink:href="BMRI2019-6502793.005"></graphic></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Knockdown of Nrf2 significantly increased the apoptosis ratio of K562/G01 cells after imatinib treatments. (a) Representative flow cytometric profiles showed the Annexin V and PI staining patterns in indicated cell lines at 28 hours after treatments with 6 <italic>μ</italic>M and 20 <italic>μ</italic>M imatinib. (b) Summary data on the percentage of apoptosis ratio (Annexin V-positive cells among total cells) in the indicated cell lines treated with (6 <italic>μ</italic>M and 20 <italic>μ</italic>M) or without (0 <italic>μ</italic>M) imatinib. <italic>n</italic> = 3 for each group; <sup><italic>∗</italic></sup><italic>p</italic> < 0.05, compared with the control group and the blank K562/G01 cells group.</p></caption><graphic xlink:href="BMRI2019-6502793.006"></graphic></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Four siRNA sequences.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">No. 1 forward strand</td><td align="center" rowspan="1" colspan="1">GCAGCAAACAAGAGATGGCAA</td></tr><tr><td align="left" rowspan="1" colspan="1">No. 1 reverse strand</td><td align="center" rowspan="1" colspan="1">TTGCCATCTCTTGTTTGCTGC</td></tr><tr><td align="left" rowspan="1" colspan="1">No. 2 forward strand</td><td align="center" rowspan="1" colspan="1">GCACCTTATATCTCGAAGTTT</td></tr><tr><td align="left" rowspan="1" colspan="1">No. 2 reverse strand</td><td align="center" rowspan="1" colspan="1">AAACTTCGAGATATAAGGTGC</td></tr><tr><td align="left" rowspan="1" colspan="1">No. 3 forward strand</td><td align="center" rowspan="1" colspan="1">CCGGCATTTCACTAAACACAA</td></tr><tr><td align="left" rowspan="1" colspan="1">No. 3 reverse strand</td><td align="center" rowspan="1" colspan="1">TTGTGTTTAGTGAAATGCCGG</td></tr><tr><td align="left" rowspan="1" colspan="1">No. 4 forward strand</td><td align="center" rowspan="1" colspan="1">CCCTGTTGATTTAGACGGTAT</td></tr><tr><td align="left" rowspan="1" colspan="1">No. 4 reverse strand</td><td align="center" rowspan="1" colspan="1">ATACCGTCTAAATCAACAGGG</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Note</italic>. No. 3 is the target sequence (from 5′ to 3′).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Target and control sequences established.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Sequence</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Frame structure</td><td align="center" rowspan="1" colspan="1">U6-vshRNA-CMV-GFP</td></tr><tr><td align="left" colspan="2" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="2" colspan="1">A framework to be established</td><td align="center" rowspan="1" colspan="1">5′-CCGG + sense strand + loop CTCGAG + antisense strand + TTTTTG-3′</td></tr><tr><td align="center" rowspan="1" colspan="1">5′-AATTCAAAAA + sense strand + loop CTCGAG + antisense strand-3′</td></tr><tr><td align="left" colspan="2" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="2" colspan="1">Targeted sequence (Nrf2-RNAi-LV)</td><td align="center" rowspan="1" colspan="1">Sense strand siRNA: CCGGCATTTCACTAAACACAA</td></tr><tr><td align="center" rowspan="1" colspan="1">Antisense strand siRNA: TTGTGTTTAGTGAAATGCCGG</td></tr><tr><td align="left" colspan="2" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="1" colspan="1">Control sequence (NC-GFP-LV)</td><td align="center" rowspan="1" colspan="1">Target sequence: TTCTCCGAACGTGTCACGT</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Primer sequences of each gene used for RT-qPCR (from 5′ to 3′).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Gene</th><th align="center" rowspan="1" colspan="1">GenBank serial number</th><th align="left" rowspan="1" colspan="1"> </th><th align="center" rowspan="1" colspan="1">Primer sequences</th><th align="center" rowspan="1" colspan="1">Product (bp)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Nrf2</td><td rowspan="2" align="center" colspan="1">NM_006164.3</td><td align="center" rowspan="1" colspan="1">Forward</td><td align="center" rowspan="1" colspan="1">ACAATGAGGTTTCTTCGGCTAC</td><td rowspan="2" align="center" colspan="1">141</td></tr><tr><td align="center" rowspan="1" colspan="1">Reverse</td><td align="center" rowspan="1" colspan="1">CGTCTAAATCAACAGGGGCTAC</td></tr><tr><td align="left" colspan="5" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="2" colspan="1">TrxR</td><td rowspan="2" align="center" colspan="1">NM_003330.2</td><td align="center" rowspan="1" colspan="1">Forward</td><td align="center" rowspan="1" colspan="1">TATCAGGAGGGCAGACTTCAA</td><td rowspan="2" align="center" colspan="1">153</td></tr><tr><td align="center" rowspan="1" colspan="1">Reverse</td><td align="center" rowspan="1" colspan="1">GACCATCACCTTCTTGCCATA</td></tr><tr><td align="left" colspan="5" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="2" colspan="1">GAPDH</td><td rowspan="2" align="center" colspan="1">BC004109</td><td align="center" rowspan="1" colspan="1">Forward</td><td align="center" rowspan="1" colspan="1">AGAAGGCTGGGGCTCATTTG</td><td rowspan="2" align="center" colspan="1">258</td></tr><tr><td align="left" rowspan="1" colspan="1">Reverse</td><td align="center" rowspan="1" colspan="1">AGGGGCCATCCACAGTCTTC</td></tr></tbody></table></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>The impacts of siRNA-mediated Nrf2 knockdown to the mRNA expressions of Nrf2 and TrxR in K562/G01 cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Gene</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">ΔCT (<inline-formula><mml:math id="M1"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mo>±</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:math></inline-formula>)</th><th align="center" rowspan="1" colspan="1">RQ (<inline-formula><mml:math id="M2"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mo>±</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:math></inline-formula>)</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Nrf2</td><td align="center" rowspan="1" colspan="1">K562/G01</td><td align="center" rowspan="1" colspan="1">3.15 ± 0.30</td><td align="center" rowspan="1" colspan="1">0.98 ± 0.21</td></tr><tr><td align="center" rowspan="1" colspan="1">NC-GFP-LV</td><td align="center" rowspan="1" colspan="1">3.23 ± 0.90</td><td align="center" rowspan="1" colspan="1">0.98 ± 0.44</td></tr><tr><td align="center" rowspan="1" colspan="1">Nrf2-RNAi-LV</td><td align="center" rowspan="1" colspan="1">4.63 ± 0.29</td><td align="center" rowspan="1" colspan="1">0.33 ± 0.09<sup><italic>∗</italic></sup></td></tr><tr><td align="left" colspan="4" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="3" colspan="1">TrxR</td><td align="center" rowspan="1" colspan="1">K562/G01</td><td align="center" rowspan="1" colspan="1">19.22 ± 0.25</td><td align="center" rowspan="1" colspan="1">1.01 ± 0.17</td></tr><tr><td align="center" rowspan="1" colspan="1">NC-GFP-LV</td><td align="center" rowspan="1" colspan="1">18.97 ± 0.68</td><td align="center" rowspan="1" colspan="1">0.92 ± 0.44</td></tr><tr><td align="center" rowspan="1" colspan="1">Nrf2-RNAi-LV</td><td align="center" rowspan="1" colspan="1">20.50 ± 0.31</td><td align="center" rowspan="1" colspan="1">0.42 ± 0.13<sup><italic>∗</italic></sup></td></tr></tbody></table><table-wrap-foot><fn><p><sup><italic>∗</italic></sup><italic>p</italic> < 0.05, compared with the uninfected K562/G01 group or NC-GFP-LV-infected group; <italic>n</italic> = 3 for each group.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000423 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000423 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:6885806
|texte= Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:31828114" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |